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here Is More Than
hape and Function*
atthias G. Friedrich, MD, FESC
algary, Alberta, Canada
“Most things break, including hearts. The lessons of life amount
not to wisdom, but to scar tissue and callus.”
—Wallace Stegner, The Spectator Bird, 1976 (1)
Cardiac arrhythmia due to cardiac hypertrophy with patchy
fibrosis of undetermined etiology. Natural Causes.
—autopsy report of Ryan Shay,
marathoner (1979–2007) (2)
eart failure has become our most important health care
oncern. Although drug therapy has made impressive ad-
ances, the prognosis of patients with symptomatic heart
ailure remains poorer than that of most malignant diseases
3). Therapeutic decisions are typically based on large-scale
rials instead of on the individual patient.
The lack of personalized treatment stems from the
bsence of clinical tools for accurately phenotyping patients
ith heart failure. The understanding is largely limited to
ymptoms and findings of the physical examination, com-
ined with data on morphology and contractile function of
he heart. Albeit useful in several clinical scenarios, this
nformation is of little help in developing disease-specific
herapeutic strategies.
See page 1574
Among serologic biomarkers, brain natriuretic peptide
BNP) is useful for taking an accurate snapshot of the
urrent severity of pressure overload, but is nonspecific
egarding the underlying disease. Inflammatory markers,
hough of prognostic value (4), are not specific to myocar-
ial disease, and their clinical role in heart failure remains to
e established. Furthermore, they do not provide relevant
nformation on the reversibility of myocardial injury or
isease-related therapeutic targets.
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Stephenson CMR Centre at the Libin Cardiovascular Institute of
lberta, University of Calgary, Departments of Cardiac Sciences and Radiology,i
algary, Alberta, Canada. Dr. Friedrich is a shareholder and member of the board of
irectors of Circle Cardiovascular Imaging Inc., Calgary, Alberta, Canada.Myocardial tissue composition holds a lot of important
nformation on disease-specific patterns of injury, current
ctivity of disease-related mechanisms such as inflamma-
ion, and the reversibility of changes. Fibrosis is the main
eature of chronic tissue damage in heart disease. Myocar-
ial infarction is the most prevalent example, and the extent
f fibrosis is the most accurate marker of injury severity.
Endomyocardial biopsy can be used to assess tissue
bnormalities such as fibrosis, but its utility in most clinical
cenarios is limited by its invasiveness and its low sensitivity
o detect regional pathology. Certain biochemical markers
re associated with fibrosis and appear promising (5).
urrent data, however, are largely experimental and there
re concerns about the specificity for myocardial fibrosis.
hus, a tool for identifying the presence and quantifying the
xtent of myocardial fibrosis would enable us to gather
mportant diagnostic and prognostic information in patients
ith heart failure.
The paper by Iles et al. (6) in this issue of the Journal
escribes a novel approach to identify and quantify diffuse
brosis using cardiovascular magnetic resonance (CMR)
maging. Using measurements of the longitudinal proton
elaxation time (T1 mapping) in post-contrast CMR im-
ges, the authors provide evidence, in patients with heart
ailure of various etiologies, that global T1 is significantly
horter than that in a control group. This effect correlated
ell with markers of diastolic function and—in a small
ubset of patients with biopsy—with the histologic amount
f tissue collagen.
There are some limitations to the study: it suffers from a
ery small sample size of subjects with histologic correlation
nd does not address potential confounders of gadolinium
istribution such as renal function, cardiac output, injection
ate, and—most importantly—timing of image acquisition
fter contrast administration. Furthermore, sequence pa-
ameters and the applicability for different hardware have to
e tested. Moreover, the data will have to be reproduced and
he added value for individual phenotyping further addressed.
But even with these limitations, this work is important,
roviding clinical proof of a concept for using basic mag-
etic properties of protons—components of virtually all
etabolites—for in vivo assessment of tissue pathology.
Many cardiologists have yet to embrace the concept of
issue characterization in clinical decision-making, and im-
ging in patients with heart failure is still very much focused
n cardiac shape and function. Ventricular volumes and
ontractility, however, may be misleading in some clinical
ettings. The 2 ends of the cardiac phenotype spectrum may
e best represented by a patient with normal ejection
raction but heart failure due to myocardial restriction and
ow cardiac output, versus a healthy endurance athlete with
ow ejection fraction and eccentric hypertrophy. Thus, there
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More Than Shape and Function November 4, 2008:1581–3Among currently available imaging modalities, magnetic
esonance imaging (MRI) stands out because of its accurate
uantitative data, but more so due to its unique image-
enerating physics, which make it especially suitable for
issue characterization. MRI signal intensity is based on
elaxation properties of protons in the static magnetic field
f a scanner. Since these properties depend on the molecular
nvironment, MRI can make use of an inherent contrast
etween different tissues. Without using tracers or contrast
gents, specific protocols of high-frequency pulses (“se-
uences”) are used to generate images with a specific tissue
ppearance. This can be used for diagnostic tissue charac-
erization, for example, looking for tissue degeneration in
rrhythmogenic right ventricular cardiomyopathy (7,8) or
yocardial edema in acute myocardial injury (9,10).
Contrast-enhanced CMR imaging is already being used
o detect tissue abnormalities and works through a region-
lly increased volume of distribution. Gadolinium-based
gents are primarily interstitial agents and, after an initial
ash-in, enter a brief (minutes) steady state with parallel
ash-in and wash-out into and from interstitial space. The
ontrast-generating mechanism of gadolinium is based on
he acceleration of proton relaxation times and a subsequent
ncrease of regional signal intensity in T1-weighted images.
his change can be observed in diseases such as myocarditis,
ith regionally increased blood volume and capillary leakage
11,12).
Necrosis and fibrosis are characterized by a substantial
ncrease in the interstitial volume of distribution for gado-
inium compounds, particularly by a significant delay of
heir washout. If CMR images are acquired late (i.e.,
etween 5 and 30 min) after gadolinium administration, the
gent will have been washed out from predominantly
ormal tissue, but will remain in regions with irreversible
njury (13). Using a specific parameter setting (a selective
requency pulse, which suppresses the magnetic resonance
ignal of normal myocardium), gadolinium-accumulating
“enhancing”) regions can be sensitively detected. This
echnique, called “late gadolinium enhancement” or “de-
ayed enhancement,” is the gold standard for the noninva-
ive assessment of infarcts and is increasingly used for
ssessing myocardial viability (14). The degree of late
nhancement appears to predict functional outcome after
evascularization (15) and future clinical events (16). Al-
hough it is a nonspecific result of any injury involving
iolent cell death, its regional distribution holds information
n the underlying etiology of myocardial disease (e.g.,
schemic, inflammatory, infiltrative, degenerative) (17–20).
Late gadolinium enhancement CMR, however, is limited
ot only by coil reception properties, field inhomogeneities,
nd artifacts, but especially in patients with predominantly
lobal, diffuse myocardial fibrosis. Because apparently nor-
al myocardium is needed to define the parameter setting
hat best suppresses its signal, it is difficult to quantify the
xtent of myocardial fibrosis if most of the tissue is affected
r if there is limited “normal” myocardium. Because the
marameter settings are “tuned” to partially fibrotic myocar-
ium, high signal intensity may not be present, despite a
lobally increased gadolinium concentration.
This gap could be filled in heart failure patients, as
uggested by Iles et al. (6), because it allows for identifica-
ion of a uniform or only slightly varying regionally different
bnormal gadolinium uptake. The idea to measure proton
elaxation time itself instead of signal intensity to detect
issue pathology is not new. In fact, as the first medical
pplication of magnetic resonance, Damadian (21) mea-
ured T1 to identify malignant tumors. But technical diffi-
ulties and lengthy protocols prevented the clinical use of
his approach. Improved hardware and software protocols
re now available (22,23) and facilitate the use of mapping
1 relaxation for clinical purposes in myocardial infarction
24) and amyloidosis (25). Initial reports on normal values
nd reproducibility indicate a reasonably small scatter to
llow for defining cut-off values for clinical decision-making
26). A broader use of this approach, however, requires
ore data, both in the normal and diseased populations, as
ell as standardized sequences and protocols. This has to
onsider contrast agent properties such as concentration,
elaxivity, and wash-in/wash-out characteristics. Further-
ore, cardiac output, injection route, and rate have to be
ddressed as potential confounders (input function). Poten-
ial solutions for these issues, such as automatic triggering
nd internal normalization, are available.
The study by Iles et al. (6) is the first report on the use of
1 mapping in phenotyping patients with heart failure, and
he authors should be congratulated for addressing an
mportant diagnostic target. If confirmed in larger samples,
1 mapping may be useful in patients with heart failure as
art of a comprehensive CMR study, providing information
n cardiac size, morphology, function, valvular function,
nd tissue characteristics. Such a scan, acquired in less than
0 minutes, not only is safe and very informative, but is also
very cost-efficient diagnostic test and allows for correlating
ultiple aspects of the disease at the very same stage of
isease.
Still perceived as complex by some, CMR already pro-
ides a uniquely wide spectrum of diagnostic targets in
ardiac diseases. It is now up to the industry and profes-
ional societies to develop and implement streamlined
rotocols, simple and fast scanning procedures, accurate
ost-processing algorithms, and suitable evaluation tools for
issue characterization.
There is more than shape and function.
eprint requests and correspondence: Prof. Matthias G.
riedrich, Stephenson CMR Centre at the Libin Cardiovascular
nstitute of Alberta, University of Calgary, Departments of Car-
iac Sciences and Radiology, SSB–Foothills Medical Centre, 1403
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